These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28874382)

  • 1. Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir.
    Garcia-Vidal E; Castellví M; Pujantell M; Badia R; Jou A; Gomez L; Puig T; Clotet B; Ballana E; Riveira-Muñoz E; Esté JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
    Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
    Chandra PK; Gerlach SL; Wu C; Khurana N; Swientoniewski LT; Abdel-Mageed AB; Li J; Braun SE; Mondal D
    Sci Rep; 2018 Oct; 8(1):14702. PubMed ID: 30279437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune regulation in HIV latency models.
    Olson RM; Gornalusse G; Whitmore LS; Newhouse D; Tisoncik-Go J; Smith E; Ochsenbauer C; Hladik F; Gale M
    Retrovirology; 2022 Jul; 19(1):15. PubMed ID: 35804422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS.
    Sarabia I; Novis CL; Macedo AB; Takata H; Nell R; Kakazu JC; Furler RL; Shakya B; Schubert HL; Hill CP; DePaula-Silva AB; Spivak AM; Trautmann L; Planelles V; Bosque A
    Front Immunol; 2021; 12():682182. PubMed ID: 34194436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.
    Brogdon J; Ziani W; Wang X; Veazey RS; Xu H
    Sci Rep; 2016 Dec; 6():39032. PubMed ID: 27941949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
    Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
    PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.
    Yang H; Buisson S; Bossi G; Wallace Z; Hancock G; So C; Ashfield R; Vuidepot A; Mahon T; Molloy P; Oates J; Paston SJ; Aleksic M; Hassan NJ; Jakobsen BK; Dorrell L
    Mol Ther; 2016 Nov; 24(11):1913-1925. PubMed ID: 27401039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.